220 related articles for article (PubMed ID: 30354917)
1. Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer.
Tang S; Zhang Q; Tang X; Chen D; Zhang F; Liu J; Wei W; Liu D
J Int Med Res; 2019 Feb; 47(2):641-652. PubMed ID: 30354917
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.
Ferreira AR; Ribeiro J; Miranda A; Mayer A; Passos-Coelho JL; Brito M; Fernandes J; Gouveia J; Costa L; Vaz-Luis I
Clin Breast Cancer; 2019 Oct; 19(5):e654-e667. PubMed ID: 31327728
[TBL] [Abstract][Full Text] [Related]
3. Breast Cancer Outcomes After Diagnosis of Hormone-positive Breast Cancer and Subsequent Pregnancy in the Tamoxifen Era.
Nye L; Rademaker A; Gradishar WJ
Clin Breast Cancer; 2017 Jul; 17(4):e185-e189. PubMed ID: 28185739
[TBL] [Abstract][Full Text] [Related]
4. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
5. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
6. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
[TBL] [Abstract][Full Text] [Related]
8. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
[TBL] [Abstract][Full Text] [Related]
9. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Tevaarwerk AJ; Wang M; Zhao F; Fetting JH; Cella D; Wagner LI; Martino S; Ingle JN; Sparano JA; Solin LJ; Wood WC; Robert NJ
J Clin Oncol; 2014 Dec; 32(35):3948-58. PubMed ID: 25349302
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
11. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
13. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
[TBL] [Abstract][Full Text] [Related]
14. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
[TBL] [Abstract][Full Text] [Related]
15. OFS plus AI or SERM vs. SERM alone in premenopausal women with hormone receptor-positive breast cancer: a prospective cohort study using the real-world database.
Hu K; He P; Peng Q; Zhong X; Deng L; Xie Y; Li J; Xu H; Lu D; Zheng H
Breast Cancer; 2019 May; 26(3):339-348. PubMed ID: 30367358
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Francis PA
Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I; Seah D; Olson EM; Wagle N; Metzger-Filho O; Sohl J; Litsas G; Burstein HJ; Krop IE; Winer EP; Lin NU
Clin Breast Cancer; 2013 Aug; 13(4):254-63. PubMed ID: 23829891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
